Revance Therapeutic (RVNC) PT Lowered to $40 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Price: $3.65 --0%
Rating Summary:
4 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
4 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Stifel analyst Annabel Samimy lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $40.00 (from $45.00) while maintaining a Buy rating.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Philip Morris (PM) PT Raised to $232 at Stifel
- Hapvida Participacoes e Investimentos SA (HAPV3:BZ) PT Lowered to R$5.60 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
